Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740358 · ClinicalTrials.gov registry record
Liver Cirrhosis Network Cohort Study
A clinical trial of Cirrhosis and Cirrhosis, Liver, sponsored by Northwestern University.
- Active
- Registry status
- 1,222
- Enrollment target
- 14
- Study locations
NCT05740358: Active study of Cirrhosis and Cirrhosis, Liver, sponsored by Northwestern University.
NCT05740358 is a study of Cirrhosis and Cirrhosis, Liver that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 1,222 participants, below the 90,386-participant average among 53 other Cirrhosis trials with a reported enrollment target (99% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05740358, a study of Cirrhosis and Cirrhosis, Liver, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- 1,222 participants
- Enrollment target
- 14
- Study locations
Study Summary
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.
Primary Outcome
Time-to-decompensation, defined as any of the following events: * Ascites: definite as determined by adjudication * Hepatic Encephalopathy (HE): definite or highly likely as determined by adjudication * Portal hypertensive upper gastrointestinal (GI) bleeding: definite as determined by adjudication
Conditions Studied
Study Locations (14)
California
- University of California San Diego NAFLD Research Center - La Jolla
- Keck Medical Center of USC - Los Angeles
- LAC + USC Medical Center - Los Angeles
- UCSF/Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- UCSF Medical Center - San Francisco
New York
- New York Presbyterian/Weill Cornell - New York
- Columbia University Iriving School of Medicine - New York
Virginia
- Central Virginia Veterans Healthcare System - Richmond
- Virginia Commonwealth University - Richmond
Florida
- University of Miami Health System - Miami
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke Liver Center - Durham
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,222 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2030-10-24 |
What the registry record for NCT05740358 still lists
NCT05740358 is an observational study that tracks outcomes without assigning an intervention. Its 1,222 participants enrollment target places it among the larger protocols in the corpus, below the 90,386-participant average among 53 other Cirrhosis trials with a reported enrollment target (99% lower).
The record links to 10 conditions, with Cirrhosis appearing as the primary indexed condition, and to 0 interventions.
NCT05740358 lists 14 locations in 8 states (California, New York, Virginia).
Frequently Asked Questions
What is clinical trial NCT05740358 about?
NCT05740358 is a clinical study titled "Liver Cirrhosis Network Cohort Study". Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants ...
What is the current status of trial NCT05740358?
This trial is currently active not recruiting. The enrollment target is 1,222 participants. The study started on 2022-11-18. Estimated completion is 2030-10-24.
What conditions does trial NCT05740358 study?
This clinical trial studies the following conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced.
Who is sponsoring clinical trial NCT05740358?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05740358 being conducted?
This trial has 14 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05740358's enrollment target sits among peer trials
1,222 6th of 53 higher than 48 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI